Uncategorized
EyeGate reports $2.4 million net loss in first quarter
EyeGate Pharmaceuticals reported a net loss of $2.4 million in the first quarter compared with a net loss of $11 million in the same quarter of 2015, according to a press release. Research and development expenses were reported at $0.9 million in the first quarter compared with $0.3 million in the same quarter of 2015. The increase was attributed to the resumption of a phase 3 clinical trial for the treatment of anterior uveitis, a phase 1/2 macular edema trial, and research and development expenses related to Jade’s CMHA-S-based product (Read more...)